BioCentury
ARTICLE | Clinical News

Nuvo's WF10 meets allergy endpoint

November 9, 2010 1:15 AM UTC

Nuvo Research Inc. (TSX:NRI) said once-daily WF10 for five consecutive days met the primary endpoint of significantly improving Total Nasal Symptom Score from baseline to three weeks vs. placebo in a ...